Thursday, July 9, 2026

Patent intelligence · US

US 12419938

Proenzyme composition

granted A61KA61K38/4826A61K9/0019A61P
Status granted
Years to expiry 19
Applicant portfolio 3
Patent details — US 12419938
Jurisdiction
US
Status
granted
Grant date
Sep 23, 2025
Expiration
Sep 18, 2045
Applicant
Propanc Pty Ltd
Claims
4
CPC classes
A61K, A61K38/4826, A61K9/0019, A61P
View on Google Patents ↗

Quick answer

US 12419938 (Proenzyme composition) is held by Propanc Pty Ltd. Status: granted. Granted Sep 23, 2025. Expires Sep 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Propanc Pty Ltd
Grant date
Expiration
Claims
4
CPC classes
A61K, A61K38/4826, A61K9/0019, A61P, A61P35/00

More from Propanc Pty Ltd

Related pharmaceutical patents in our USPTO index.

  1. US 11376313

    Cancer treatment

    Propanc Pty Ltd · Expires Jun 30, 2042

    granted
  2. US 10350239

    Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

    Propanc Pty Ltd · Expires Jul 11, 2039

    granted

Frequently asked questions

What is US patent 12419938?

US 12419938 (Proenzyme composition) is held by Propanc Pty Ltd. Status: granted. Granted Sep 23, 2025. Expires Sep 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12419938?

Propanc Pty Ltd is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.

When does US 12419938 expire?

Our index shows an expiration date of Sep 18, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.